Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.